Health Condition 1: null- Patients with Acute viral hepatitis due to HEV and Acute on chronic liver failure with HEV
Conditions
Interventions
Intervention1: Tab zinc (acetate) dose 50 mg: 50 mg Zinc acetate twice a day for two weeks duration
Control Intervention1: Placebo: Placebo will be given twice a day for 2 weeks
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria (for AVH): 1) Age > 18 years with Acute viral hepatitis due to HEV 2) Duration of symptoms 3) Written informed consent Inclusion criteria (for ACLF) 1) Age > 18 years with Acute on chronic liver failure with HEV as acute precipitant. 2) Written informed consent Inclusion criteria (for HEV-ALF) 1) Age > 18 years with Acute liver failure due to HEV. 2) Written informed consent from patient or relatives
Exclusion criteria
Exclusion criteria: 1) Chronic renal insufficiency (creatinine level, > 2.0mg/dl) 2) Patients diagnosed with Acute Kidney Injury. 3) Respiratory insufficiency 4) Anaemia, haemoglobin 5) Coexistent bacterial infection 6) Associated hepatocellular carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) To study the effect of Zinc supplementation on recovery of liver function tests at the end of 1st week and 2nd weekTimepoint: 1) End of 1st week and 2nd week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To evaluate the effect of Zinc supplementation on the duration of HEV viremia (Stool and Blood) and cytokine profile. 2) To evaluate the safety and efficacy of Zinc therapy in patients with HEV infection. Timepoint: day 0, 5, 10 and 15 | — |
Countries
India
Contacts
Public ContactDr Shalimar
All India Institute of Medical Sciences
Outcome results
None listed